The modular design of ARIBOTAC technology offers a high degree of programmability: (1) different miRNAs (e.g., let-7 family or miR-155) can be targeted by replacing the ASO sequence; (2) the aptamer element can be substituted with other tumor-specific ligands such as EpCAM or PSMA; and (3) the entire structure, including the 2′–5′A activation module, can be optimized to enhance nuclease resistance. Here, FOLH1 is linked to neoplasm.